Which statement best describes the role of P2Y inhibitors in ACS management?

Which statement best describes the role of P2Y inhibitors in ACS management?

• A. They are calcium channel blockers
• B. They are antiplatelet agents
• C. They are anticoagulants
• D. They are beta blockers

Answer: (B)

P2Y inhibitors work by blocking the P2Y12 receptor on platelets, which ADP normally binds to in order to promote platelet activation and aggregation. In acute coronary syndrome, platelets are highly activated and contribute to thrombus formation in the culprit artery; by inhibiting this pathway, P2Y inhibitors reduce platelet aggregation and lower the risk of recurrent ischemia. They are antiplatelet agents, typically used with aspirin as part of dual antiplatelet therapy. They are not calcium channel blockers, which affect calcium entry to smooth muscle and cardiac tissue; not anticoagulants, which target the coagulation cascade; and not beta blockers, which reduce heart rate and myocardial oxygen demand without directly preventing platelet aggregation. Examples include clopidogrel, prasugrel, and ticagrelor.

P2Y inhibitors work by blocking the P2Y12 receptor on platelets, which ADP normally binds to in order to promote platelet activation and aggregation. In acute coronary syndrome, platelets are highly activated and contribute to thrombus formation in the culprit artery; by inhibiting this pathway, P2Y inhibitors reduce platelet aggregation and lower the risk of recurrent ischemia. They are antiplatelet agents, typically used with aspirin as part of dual antiplatelet therapy. They are not calcium channel blockers, which affect calcium entry to smooth muscle and cardiac tissue; not anticoagulants, which target the coagulation cascade; and not beta blockers, which reduce heart rate and myocardial oxygen demand without directly preventing platelet aggregation. Examples include clopidogrel, prasugrel, and ticagrelor.